Form D · Pharmaceuticals

Clene Inc.

Salt Lake City, UT · CIK 0001822791

Offering snapshot reported Oct 9, 2024 · SEC filing

Reported sold
$7.31M
Offering amount: $7.31M
Investors reported
13
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Oct 1, 2024
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Oct 9, 2024Initial$7,310,060No comparison13SEC filing
May 26, 2021Initial$9,250,000No comparisonNot reportedSEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$437K
Finders' fees
$0
Form D file number
021-526349

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Canaccord Genuity LLC1020

Source: Form D, filed Oct 9, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Morgan Brown Executive
Fiona Costello Director
Arjun Desai Director
Robert Dee Etherington Director, Executive
Jonathon T. Gay Director
Robert Glanzman Executive
Shalom Jacobovitz Director
Tae Heum Jeong Executive
Matthew Kiernan Director
David Matlin Director
Vallerie V. Mc Laughlin Director
Mark Mortenson Executive
Alison Mosca Director
John Stevens Director
Chidozie Ugwumba Director
Reed Neil Wilcox Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
6550 South Millrock Drive, Suite G50
Salt Lake City, UT, 84121